{"success":true,"data":{"pressRelease":{"id":"76219","rtpr_id":"nGNX9LdycX","ticker":"0013","exchange":"HKEX","all_tickers":["0013"],"title":"HUTCHMED to Announce 2026 Half-Year Financial Results","author":"Globe Newswire","published_at":"2026-06-30T08:30:00.124Z","article_body":"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE)\n-- HUTCHMED (China) Limited (“HUTCHMED\n(https://www.globenewswire.com/Tracker?data=V8iYsbGhLgHFa7p_h-t1glfMUfhYPfVJyCl7CaoZqI7qfzB68SgDV-I-7rDd28LkZUfen6mg_TbwQsEZuxtxCg==)”)\n(Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six\nmonths ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern\nDaylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong\nTime (HKT).\n\nHUTCHMED management will host two webcast presentations for analysts and\ninvestors to discuss the interim results, followed by Q&A sessions. The\nEnglish webcast will be held on Thursday, July 30, 2026, at 8:00 am EDT / 1:00\npm BST / 8:00 pm HKT. The Chinese (Putonghua) webcast will be held at 8:30 am\nHKT on Friday, July 31, 2026 (1:30 am BST / 8:30 pm EDT on Thursday, July 30,\n2026).\n\nBoth webcasts will be available live via the company website at\nwww.hutch-med.com/event/. The presentation will be available to download\nshortly before the webcast begins. A replay will also be available on the\nwebsite shortly after the event.\n\nAbout HUTCHMED\n\nHUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage,\nbiopharmaceutical company. It is committed to the discovery and global\ndevelopment and commercialization of targeted therapies and immunotherapies\nfor the treatment of cancer and immunological diseases. Since inception it has\nfocused on bringing drug candidates from in-house discovery to patients around\nthe world, with its first three medicines marketed in China, the first of\nwhich is also approved around the world including in the US, Europe and Japan.\nFor more information, please visit: www.hutch-med.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=I0hZ-Xy0NpUNO1dqLqJR1LPnkdQThHHs7u70yog4SnFtgQEe8Z4ohLpWfeaBIvsVcHh5ETAc5Xzo03SG3IR5THDXmtNYgPVJlXLcAhMG6qA=).\n\nCONTACTS\n\n Investor Enquiries                           +852 2121 8200 / ir@hutch-med.com                      \n                                                                                                     \n Media Enquiries                                                                                     \n FTI Consulting –                             +44 20 3727 1030 / HUTCHMED@fticonsulting.com          \n Ben Atwell / Tim Stamper                     +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)  \n Brunswick – Zhou Yi                          +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com  \n                                                                                                     \n Panmure Liberum                              Nominated Advisor and Joint Broker                     \n Atholl Tweedie / Emma Earl / Rupert Dearden  +44 20 7886 2500                                       \n                                                                                                     \n Cavendish                                    Joint Broker                                           \n Geoff Nash / Nigel Birks                     +44 20 7220 0500                                       \n                                                                                                     \n Deutsche Numis                               Joint Broker                                           \n Duncan Monteith / Ramin Naji                 +44 20 7545 8000                                       \n                                                                                                     \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/085957ad-3bec-49ee-b13e-39961b83c7be)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9LdycX","title":"HUTCHMED to Announce 2026 Half-Year Financial Results","author":"Globe Newswire","ticker":"0013","created":"2026-06-30T08:30:00.124Z","tickers":["0013"],"exchange":"HKEX","article_body":"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE)\n-- HUTCHMED (China) Limited (“HUTCHMED\n(https://www.globenewswire.com/Tracker?data=V8iYsbGhLgHFa7p_h-t1glfMUfhYPfVJyCl7CaoZqI7qfzB68SgDV-I-7rDd28LkZUfen6mg_TbwQsEZuxtxCg==)”)\n(Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six\nmonths ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern\nDaylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong\nTime (HKT).\n\nHUTCHMED management will host two webcast presentations for analysts and\ninvestors to discuss the interim results, followed by Q&A sessions. The\nEnglish webcast will be held on Thursday, July 30, 2026, at 8:00 am EDT / 1:00\npm BST / 8:00 pm HKT. The Chinese (Putonghua) webcast will be held at 8:30 am\nHKT on Friday, July 31, 2026 (1:30 am BST / 8:30 pm EDT on Thursday, July 30,\n2026).\n\nBoth webcasts will be available live via the company website at\nwww.hutch-med.com/event/. The presentation will be available to download\nshortly before the webcast begins. A replay will also be available on the\nwebsite shortly after the event.\n\nAbout HUTCHMED\n\nHUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage,\nbiopharmaceutical company. It is committed to the discovery and global\ndevelopment and commercialization of targeted therapies and immunotherapies\nfor the treatment of cancer and immunological diseases. Since inception it has\nfocused on bringing drug candidates from in-house discovery to patients around\nthe world, with its first three medicines marketed in China, the first of\nwhich is also approved around the world including in the US, Europe and Japan.\nFor more information, please visit: www.hutch-med.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=I0hZ-Xy0NpUNO1dqLqJR1LPnkdQThHHs7u70yog4SnFtgQEe8Z4ohLpWfeaBIvsVcHh5ETAc5Xzo03SG3IR5THDXmtNYgPVJlXLcAhMG6qA=).\n\nCONTACTS\n\n Investor Enquiries                           +852 2121 8200 / ir@hutch-med.com                      \n                                                                                                     \n Media Enquiries                                                                                     \n FTI Consulting –                             +44 20 3727 1030 / HUTCHMED@fticonsulting.com          \n Ben Atwell / Tim Stamper                     +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)  \n Brunswick – Zhou Yi                          +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com  \n                                                                                                     \n Panmure Liberum                              Nominated Advisor and Joint Broker                     \n Atholl Tweedie / Emma Earl / Rupert Dearden  +44 20 7886 2500                                       \n                                                                                                     \n Cavendish                                    Joint Broker                                           \n Geoff Nash / Nigel Birks                     +44 20 7220 0500                                       \n                                                                                                     \n Deutsche Numis                               Joint Broker                                           \n Duncan Monteith / Ramin Naji                 +44 20 7545 8000                                       \n                                                                                                     \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/085957ad-3bec-49ee-b13e-39961b83c7be)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-30T08:30:00.157920488Z","server_sent_at_ms":1782808200157},"received_at":"2026-06-30T08:30:00.208Z","source_url":null},"analysis":{"id":"65495","press_release_id":"76219","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"HUTCHMED scheduled the release of its 2026 interim results for July 30, 2026, and announced details for two investor webcasts to discuss the findings.\n\nThe English webcast is set for July 30 at 8:00 am EDT, followed by a Chinese-language webcast the next morning in Hong Kong.\n\nManagement will be available for Q&A during both sessions; replays will be accessible on the company website shortly after the events.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine earnings calendar update; no action required until results are released."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Ben Atwell","role":"Media Contact"},{"name":"Tim Stamper","role":"Media Contact"},{"name":"Zhou Yi","role":"Media Contact"},{"name":"Atholl Tweedie","role":"Nominated Advisor and Joint Broker"},{"name":"Emma Earl","role":"Nominated Advisor and Joint Broker"},{"name":"Rupert Dearden","role":"Nominated Advisor and Joint Broker"},{"name":"Geoff Nash","role":"Joint Broker"},{"name":"Nigel Birks","role":"Joint Broker"},{"name":"Duncan Monteith","role":"Joint Broker"},{"name":"Ramin Naji","role":"Joint Broker"}],"products":[],"companies":[{"name":"HUTCHMED (China) Limited","ticker":"HCM","relationship":"issuer"},{"name":"FTI Consulting","relationship":"Media Relations"},{"name":"Brunswick","relationship":"Media Relations"},{"name":"Panmure Liberum","relationship":"Nominated Advisor and Joint Broker"},{"name":"Cavendish","relationship":"Joint Broker"},{"name":"Deutsche Numis","relationship":"Joint Broker"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine notification of an upcoming earnings release and webcast scheduling. No financial data or material developments disclosed."},"tickerRelevance":{"others":[{"ticker":"HCM","relevance":"primary listing (Nasdaq/AIM)"}],"primary":"0013"},"globalImportance":10,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"earnings-schedule","sectorWeight":"biotech"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"HUTCHMED scheduled the release of its 2026 interim results for July 30, 2026, and announced details for two investor webcasts to discuss the findings.\n\nThe English webcast is set for July 30 at 8:00 am EDT, followed by a Chinese-language webcast the next morning in Hong Kong.\n\nManagement will be available for Q&A during both sessions; replays will be accessible on the company website shortly after the events.","key_figures":null,"named_entities":{"people":[{"name":"Ben Atwell","role":"Media Contact"},{"name":"Tim Stamper","role":"Media Contact"},{"name":"Zhou Yi","role":"Media Contact"},{"name":"Atholl Tweedie","role":"Nominated Advisor and Joint Broker"},{"name":"Emma Earl","role":"Nominated Advisor and Joint Broker"},{"name":"Rupert Dearden","role":"Nominated Advisor and Joint Broker"},{"name":"Geoff Nash","role":"Joint Broker"},{"name":"Nigel Birks","role":"Joint Broker"},{"name":"Duncan Monteith","role":"Joint Broker"},{"name":"Ramin Naji","role":"Joint Broker"}],"products":[],"companies":[{"name":"HUTCHMED (China) Limited","ticker":"HCM","relationship":"issuer"},{"name":"FTI Consulting","relationship":"Media Relations"},{"name":"Brunswick","relationship":"Media Relations"},{"name":"Panmure Liberum","relationship":"Nominated Advisor and Joint Broker"},{"name":"Cavendish","relationship":"Joint Broker"},{"name":"Deutsche Numis","relationship":"Joint Broker"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-30T08:32:32.065Z","global_importance":10,"audience_relevance":20,"importance_components":{"tickerTier":"mid-cap","eventGravity":"earnings-schedule","sectorWeight":"biotech"}},"durationMs":151850,"modelName":"george-droid-qwen-72b"}}